Functional selectivity through protean and biased agonism: who steers the ship? - PubMed (original) (raw)
Review
. 2007 Dec;72(6):1393-401.
doi: 10.1124/mol.107.040352. Epub 2007 Sep 27.
Affiliations
- PMID: 17901198
- DOI: 10.1124/mol.107.040352
Review
Functional selectivity through protean and biased agonism: who steers the ship?
Terry Kenakin. Mol Pharmacol. 2007 Dec.
Abstract
This article describes functional selectivity of agonists and antagonists and distinguishes conventional cell-based functional selectivity, where the strength of signal produces selective signaling in various organs, from true receptor active-state based selectivity, also alternatively referred to in the literature as "stimulus trafficking," "biased agonism," and "collateral efficacy." This latter mechanism of selectivity depends on the ligand-related conformation of the receptor and is not compatible with the parsimonious view that agonists produce a single receptor active state. In addition, protean agonism is described, whereby a ligand produces positive agonism in quiescent systems and inverse agonism in constitutively active systems. This is a special case of active state-based selectivity in which the ligand produces an active state that is of lower efficacy than the natural constitutively active state. It is postulated that receptor active-state based selectivity, unlike cell-based functional selectivity, is controllable through the chemical structure of the ligand and is therefore more likely to be a viable avenue for therapeutic selectivity in the clinic. Reasons are given for differentiating receptor active-state based selectivity from conventional functional organ selectivity.
Similar articles
- The evasive nature of drug efficacy: implications for drug discovery.
Galandrin S, Oligny-Longpré G, Bouvier M. Galandrin S, et al. Trends Pharmacol Sci. 2007 Aug;28(8):423-30. doi: 10.1016/j.tips.2007.06.005. Epub 2007 Jul 19. Trends Pharmacol Sci. 2007. PMID: 17659355 Review. - Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.
Kenakin T. Kenakin T. Trends Pharmacol Sci. 2007 Aug;28(8):407-15. doi: 10.1016/j.tips.2007.06.009. Epub 2007 Jul 13. Trends Pharmacol Sci. 2007. PMID: 17629960 Review. - Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
Kenakin T. Kenakin T. Mol Pharmacol. 2004 Jan;65(1):2-11. doi: 10.1124/mol.65.1.2. Mol Pharmacol. 2004. PMID: 14722230 Review. - The role of conformational ensembles of seven transmembrane receptors in functional selectivity.
Vaidehi N, Kenakin T. Vaidehi N, et al. Curr Opin Pharmacol. 2010 Dec;10(6):775-81. doi: 10.1016/j.coph.2010.09.004. Curr Opin Pharmacol. 2010. PMID: 20933468 Review. - Molecular basis of inverse agonism in a G protein-coupled receptor.
Vilardaga JP, Steinmeyer R, Harms GS, Lohse MJ. Vilardaga JP, et al. Nat Chem Biol. 2005 Jun;1(1):25-8. doi: 10.1038/nchembio705. Epub 2005 May 24. Nat Chem Biol. 2005. PMID: 16407989
Cited by
- CXCL12 chemokine dimer signaling modulates acute myelogenous leukemia cell migration through altered receptor internalization.
Drouillard D, Halyko M, Cinquegrani E, McAllister D, Peterson FC, Marchese A, Dwinell MB. Drouillard D, et al. bioRxiv [Preprint]. 2024 Aug 27:2024.08.26.609725. doi: 10.1101/2024.08.26.609725. bioRxiv. 2024. PMID: 39253415 Free PMC article. Preprint. - Advances in attenuating opioid-induced respiratory depression: A narrative review.
Fan YZ, Duan YL, Chen CT, Wang Y, Zhu AP. Fan YZ, et al. Medicine (Baltimore). 2024 Jul 19;103(29):e38837. doi: 10.1097/MD.0000000000038837. Medicine (Baltimore). 2024. PMID: 39029082 Free PMC article. Review. - Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.
Baker JG, Summers RJ. Baker JG, et al. Handb Exp Pharmacol. 2024;285:55-145. doi: 10.1007/164_2024_713. Handb Exp Pharmacol. 2024. PMID: 38926158 Review. - Kinetic insights into agonist-dependent signalling bias at the pro-inflammatory G-protein coupled receptor GPR84.
Luscombe VB, Baena-López LA, Bataille CJR, Russell AJ, Greaves DR. Luscombe VB, et al. Eur J Pharmacol. 2023 Oct 5;956:175960. doi: 10.1016/j.ejphar.2023.175960. Epub 2023 Aug 3. Eur J Pharmacol. 2023. PMID: 37543157 Free PMC article. - [18F]F13640: a selective agonist PET radiopharmaceutical for imaging functional 5-HT1A receptors in humans.
Courault P, Lancelot S, Costes N, Colom M, Le Bars D, Redoute J, Gobert F, Dailler F, Isal S, Iecker T, Newman-Tancredi A, Merida I, Zimmer L. Courault P, et al. Eur J Nucl Med Mol Imaging. 2023 May;50(6):1651-1664. doi: 10.1007/s00259-022-06103-1. Epub 2023 Jan 19. Eur J Nucl Med Mol Imaging. 2023. PMID: 36656363 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources